Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell, kissing- up to the fundamentals we stand with

May 19, 2017 6:26pm

As the sector gripped the handrail to stay up …

Let’s stop staring at the wall of worry and jump or climb over

Pre-open indications: 5 hits and 0 miss

Out and about: Biostage (BSTG) is non-compliant with its NASDAQ listing with no investor notice on second extension as a wrongful death complaint (suit) complicates their viability as on-going concern and any potential reverse and warrant exercise! Don’t investors have a RIGHT to be informed!

As the leading voice of cell therapy investors; I am not always a doom and gloom reporter but a man who has been “there” with the gray hair and a readership following with real numbers to prove it!

I answer one question, in which company should investors commit and keep their money

RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds - just because a stock underperforms the market doesn’t mean you have to lose money.

Henry’omics:

From the pre-open’s investor’s newsletter … “I’ve grown accustomed to the volatility. Traders love it while investors are reminded that “our” universe’s stocks are risky assets.”

Reiterating, “Time to play switcheroo on BUYING and SELLING … That’s how I define volatility and making money in this sector.”

On Friday, the week of volatility, socks diving and jumping can’t be dismissed; we must remember that when Q1 quarterlies were initiated - the sector reacted, but the results ran down the sector with stocks selling- off.

I keep writing about sentiment – it can’t be sustained along with pricing …

The word for the second quarter must be sustainability!

Let’s stay far away from the “wall of worry”!

Pre-open indications: 5 hit and 0 miss

bluebird bio (BLUE) closed down -$6.00 – hit;
Juno Therapeutics (JUNO) closed down -$1.36 – hit;
Kite Pharma (KITE) closed down -$1.78 – hit;
Neuralstem (CUR) closed down -$0.29 – hit;
Sangamo (SGMO) closed down -$0.15 – hit;

Out and about:

Biostage’s (BSTG) non-compliant with NASDAQ listing …

A Notification Letter indicated that BSTG had been provided an initial period of 180 calendar days, or until May 17, 2017, in which to regain compliance. If BSTG is unable to regain compliance with the bid price requirement by May 17, 2017, NASDAQ may grant an additional 180-day period to regain compliance.

That will be their third (3^rd extension) as the stock closed at $0.30

A history of a depreciating share price …

Q2/17 – high of $0.34 and a low (so far) of $0.30

Q1/17 – high of $0.87 and a low of $0.37

Q1/16 – high of $2.60 and a low of $1.08

Q2/16 – high of $2.86 and a low of $0.92

Q3/16 – high of $1.22 and a low of $0.90

Q4/16 – high of 1.42 and a low of 0.73 which followed

Q1/15 – a high of $4.43 and a low of $1.85

Another metric to be considered … Short ratio – 2.13% or 2.86 M shares of a float of 34.12 M shares

……… NON-COMPLIANT …… Don’t investors have a RIGHT to be informed!

Daily analytics:

U.S. equities closed DOWN on Friday … with the DOW closing UP +0.0.69% (+141.82) as the NASDAQ also closed UP +0.47% (+28.57) …

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded at 12.2.

·Thursday closed at 14.6 down -5.97% following Wednesday ‘s 15.59 – a 44% increase, Tuesday’s 10.56, Monday’s near 10.4 as last Friday’s traded below 10;

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated a positive +0.29% at the pre-open and closed UP +0.48% following Thursday +0.36, Wednesday’s -2.70%, Tuesday’s +0.04% and Monday’s +0.78%

… The iShares NASDAQ Biotechnology (IBB) indicate a positive +0.26% in the pre-open and closed DOWN -0.62% following Thursday’s +1.28, Wednesday -2.27%, Tuesday’s +0.40% and Monday’s +0.43%

The advance/decline line scenario of 43 SCGT & RT covered companies:

· The open was positive with an A/DL of 28/9 and 6 flats;

· The mid-day was positive with an A/DL of 23/17 and 3 flat3;

· The close was positive with an A/DL of 26/15 and 2 flats;

The count - decliners versus gainers: look at the differences in the spreads and advance/decline lines:

· Friday’s decliners ranged from -0.17% <BSTG> to -6.78% <BLUE> in 15 equities;

· Thursday’s decliners ranged from -0.32% <KOOL> to -6.42% <AGTC> in 13 equities;

· Wednesday’s decliners ranged from -0.47% <BLFS> to -9.23% <OSIR> in 39 equities;

· Tuesday’s decliners ranged from -0.19% <ONCE> to -23.27% <IMUC> in 19 equities;

· Monday’s decliners ranged from -0.04% <KITE> to -4.41% <MESO> in 12 equities;

Versus

· Friday’s gainers ranged from +0.01% <HSGX> to +10.66% <QURE> in 26 equities;

· Thursday’s gainers ranged from +0.35% <MDXG> to +16.46% <CUR> in 25 equities;

· Wednesday’s gainers ranged from +0.72% <AXGN> to +6.83% <ISCO> in 4 equities;

· Tuesday’s gainers ranged from +0.06% <BLUE> to +10.33% <OPXA> in 23 equities;

· Monday’s gainers ranged from +0.19% <BSTG> to +9.50% <FCSC> in 27 equities;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.